Metraipolis › archive › dc_95b4002ea057
Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: A randomized phase 3 Asian study — Europe PMC PMID:42154070
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42154070
- DOI
- 10.1007/s00277-[numero omesso]-z
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-01T14:36:51.347Z
- SHA-256 of the archived text
29fcd6ac4acfb0f8919839853de044744cf220177b53bfb268afdadd76ff397e- Stable URL of this page
https://metraipolis.com/documento/dc_95b4002ea057
How to cite
Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: A randomized phase 3 Asian study — Europe PMC PMID:42154070 — Europe PMC (en), https://europepmc.org/article/MED/42154070 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_95b4002ea057 (Metraipolis archive dc_95b4002ea057, sha256 29fcd6ac4acfb0f8919839853de044744cf220177b53bfb268afdadd76ff397e)
BibTeX
@misc{dc95b4002ea057,
title = {Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: A randomized phase 3 Asian study — Europe PMC PMID:42154070},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42154070},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_95b4002ea057; sha256 29fcd6ac4acfb0f8919839853de044744cf220177b53bfb268afdadd76ff397e},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42154070. Agents can read the archived copy with the MCP tool read_document.